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Executive Summary
U.S. taxpayers funded $14.8 billion of health related research lastyear, four
times the amount that was spent in 1970 in real terms. In thispaper we evaluate
the impact of these huge expenditures on the technologicalperformance of the
pharmaceutical industry. While it is very difficult to be precise aboutthe pay-
offs from publicly funded research, we conclude froma survey of a wide vari-
ety of quantitative and qualitative academic studies that thereturns from this
investment have been large, and may be growingeven larger. Public sector sci-
ence creates new knowledge and new tools, and produces large numbers of
highly trained researchers, all of which area direct and important input to pri-
vate sector research. But this is not a one way street: the downstreamindustry
is closely linked with upstream institutions, and knowledge,materials, and
people flow in both directions. One important contribution ofpublic science is
that it sustains an environment in which for-profit firmscan conduct their own
basic research, which in turn contributes to the global pool ofknowledge. Mea-
sured quite narrowly in terms of its effect on privatesector R&D, the rate of re-
turn to public funding of biomedical sciences may beas high as 30% per year.
Large as this figure is, these calculationsare likely an underestimate, since they
fail to fully capture the wider impact of pharmaceuticalinnovation on health
and well-being. Indeed, the best may be yet tocome: the revolution in molecu-
lar biology that began in publicly funded laboratories 25years agoand con-
tinues to be driven by the academic researchpromises dramaticadvances in
the treatment of disease.
I.Introduction
Between 1970 and 1999, public funding in the U.S. for healthrelated re-
search increased over 400% in real terms, to $14.8 billion,or 38% of the
non-defense Federal research budget. Worldwide, the U.S.spends
more of its publicly available research funds on human health thanany
other nation (table 1.1). What kind of impact is thisresearch having? Is2 Cockburn and Henderson
Table 1.1
National expenditures on academic and related research by mainfield, 1987
aExpenditure data are based on OECD "purchasing power parities" for1987 calculated
in early 1989.
bTins represents an unweighted average for the six countries (i.e., national figures have
not been weighted to take into account the differing sizeof countries).
Irvine, J., B. Martin, and P. Isard 1990 p. 219.
the public getting an appropriate "bang for itsbuck"? This paper ex-
plores one aspect of this question by focusing on oneissue in particu-
lar: the impact of publicly funded research onthe productivity of the
U.S. pharmaceutical industry.
The pharmaceutical industry provides aparticularly interesting win-
dow through which to study the more generalquestion of the impact of
publicly funded research. The public sector probablyplays a more im-
portant role in determining private sectorproductivity in the pharma-
ceutical industry than in any other industry exceptdefense. Public
sector research spending almost equalsprivate sector spending, and
publicly funded researchers generate a disproportionateshare of the
papers published in the relevantfields (Stephan 1996). It is also the case
that scientific advances in medical practice appear tohave had a very
significant effect on human health. Between 1940 and1990, average life
expectancy in the U.S. increased from63.6 to 75.1 years, and the aver-
age quality of life appears to havealso increased over the same time pe-
riod (Cutler and Richardson 1999). While advancesin human health
have many causes, advances inpharmaceutical therapies have made a
very significant contribution.New drugs have revolutionized the treat-
Expenditure (1987 M$)
U.K. FRG FranceNeth. U.S. JapanAverageb
Engineering 436 505 359 112 1,966 809 14.3%
15.6% 12.5%11.2% 11.7%13.2%21.6%
Physical 565 1,015 955 208 2,325 543 21.2%
Sciences 20.2%25.1%29.7% 21.7% 15.6% 14.5%
Life Sciences 864 1,483 1,116 313 7,285 1,261 36.3%
30.9%36.7%34.7% 32.7%48.9% 33.7%
Social Sciences187 210 146 99 754 145 6.0%
6.7% 5.2% 4.6% 10.4%5.1% 3.9%
Arts & 184 251 218 83 411 358 6.8%
Humanities 6.6% 6.2% 6.8% 8.6% 2.8% 9.6%
Other 562 573 418 143 2,163 620 15.6%
20.1%14.2%13.0% 14.9%14.5% 16.6%
Total 2,798 4,037 3,212 958 14,9043,736Public Funding and Pharmaceutical Productivity 3
ment of ulcers, stroke, and various psychiatric conditions. They have
dramatically improved the quality of life of asthma sufferers. They
have brought the symptoms of AIDS under control fora significant
fraction of the infected population. Somecancers are now reliably cur-
able by drug therapy, and new drugs for hypertension and high choles-
terol are proving instrumental in the treatment of heart disease, stifi the
largest killer of Americans. Drugs "in the pipeline" promise major ad-
vances in the treatment of arthritis, Alzheimer's disease, many kinds of
cancers and a variety of other chronic conditions. Since there is general
agreement among qualified observers that publicly funded science has
played a major role in these advances, the industry presentsa particu-
larly salient setting in which to explore its economic impact.
This paper begins by briefly reviewing theprogress that has been
made in estimating the rate of return to publicly funded science in
other settings. Efforts to measure the rate of return to public research in
any context are dogged by a variety of difficult practical and concep-
tual problems (Griliches 1979; Jones and Williams 1995), andmany of
these problems are particularly severe in thecase of the pharmaceutical
industry. We outline some of the difficulties inherent ingenerating
quantitative estimates, and summarize some key results. Although
measuring the research output of the public sector and its impacton
the rest of the economy presents enormous challenges, both quantita-
tive and qualitative estimates suggest that the rate of return to basicre-
search in general is probably quite high. Case studies of specific
technologies and government programs point to the critical role of
public sector research in laying the foundation for technological ad-
vances that have later had enormous impact on the civilian economy
(see for example David, Mowery, and Steinmuller 1992), and direct
quantitative estimates suggest that the rate of return to publicly funded
research is on the order of 25-40%, (Adams 1990; Mansfield 1991;
Griliches 1979, 1994).
The paper then turns to a discussion of the pharmaceutical industry
We show that publicly funded research has increased dramaticallyover
the last 60 years, and present some evidence suggesting that its role has
become increasingly important. While pharmaceutical research in the
1960s and 1970s drew upon the results of federally funded research,
it typically took many years for the results of publicly funded work
to have an impact on the private sector, and many firms made only
limited use of publicly generated results. The revolution in molecular
biology and the transition to "rational" or "mechanism driven" drug4 Cockburn and Henderson
design and then to the techniques of biotechnology haverevolution-
ized the relationship between the public and private sectors,making
immediate access to leading edge publicly funded science a key com-
petitive advantage for leading pharmaceutical firmsand stimulating
the development of an entirely new segment of the industry:the small
biotechnology firm. While early research in the industryfollowed a
more traditional waterfall model,with the results of publicly funded
research gradually flowing downhill to the private sector, overthe last
25 years the relationship has become much more thatof an equal part-
nership, with ideas and materials flowing upstream tothe public sector
as well as downstream toindustry.
This is followed by a discussion of the quantitativeevidence. We
show that many of the problems that make the measurementof the im-
pact of publicly funded research difficult in the wider economyoperate
with particular force here: it is quite difficult to measureeither the
"output" of publicly funded research or its impact onthe private sec-
tor, there are long and variable lags betweenthe generation of knowl-
edge in the public sector and its impact in industry,and there are many
different pathways through which the public sector shapes private sec-
tor research. The public sector generates morethan just scientific pa-
pers, pure knowledge, and highlytrained graduates: its existence also
supports a community of "open science" that sustainshigh quality pri-
vately funded research in the for-profit laboratories.
While it is, therefore, very hard to precisely estimate the return to
publicly funded biomedical research, we nonetheless concludethat it is
quite high. On the one hand, the qualitative evidenceis compelling: the
U.S. pharmaceutical and biotechnology industrieslead the world, and
while there are a variety of plausible reasons for this, thestrength of the
public research base is surely among the most important.Detailed case
studies have highlighted the role of the public sector insupporting the
development of important new drugs, and almost universalagreement
among private sector researchers thatpublicly funded research is vital
to all that they do. There are also a numberof econometric studies that,
while imperfect and undoubtedly subject to improvementand revi-
sion, between them make a quite convincing casefor a high rate of re-
turn to public science in this industry. It isworth noting that there are,
so far as we are aware, nosystematic quantitative studies that have
found a negative impact of public science!
We conclude the paper with a brief summary and somespeculations
as to the future. The ongoingrevolution in genetics, genomics, andPublic Funding and Pharmaceutical Productivity
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bioinformaticsall advances that have theirroots squarely in federally
funded researchpromisesto revolutionize the treatment ofmany dis-
eases. If this promise is realized, the role of publiclyfunded research in
advancing human health throughthe support of pharmaceuticalinno-
vation will be beyond question. Thisis an exciting period in whichto
be studying the impact of publiclyfunded research.
II.Measuring the Impact of PubliclyFunded Research:
The General Problem
Government funding for "basic"or "fundamental" research has tradi-
tionally been justified on the groundsthat the social returns to basicre-
search are likely to significantlyexceed private returns, and thusthat
the private sector will underinvestin basic research relativeto the so-
cial optimum (Nelson 11959; Arrow1962). Private firmsare unlikely to
be able to capture (or "appropriate")the returns to basic research be-
cause, in general, it usually takes avery long time for the practical im-
plications of basic researchto become apparent and becausethese
implications are often highly diffuse.A firm that is funding basicre-
search in optics, for example, mightnot see any returnon its invest-
ment for many years, andmany of these returns might be realized by
its competitors or by firmscompeting in entirely different industries.
There is also some evidence thatbasic research has its greatestimpact
when it is funded by the publicsector because publicly fundedre-
searchers are more likely tocompete for prestige in their fields thanfor
financial gain, and since prestigeis gained through the rapidpublica-
tion of their results, publicly fundedresearch is likely to becomemore
rapidly available across theeconomy than privately funded work
(Dasgupta and David 1987, 1994;Merton 1973).
Unfortunately exactly thesame characteristics that make it economi-
cally desirable for thegovernment to fund basic researchthe long
lags between research and impactand its wide diffusionacross firms
and industriesalso make itvery difficult to measure its effects. Two
techniques have been widely used:case studies and econometricpro-
duction function based analysis.The available case studiesare sugges-
tive, and most of themsuggest that government funded researchhas
indeed had a significant effecton private sector productivity (see, for
example, David, Mowery, andSteinmuller 1992; Mansfield 1991;and
the NSF 1968), but it is alwaysdifficult to know how farone can gener-
alize from the results ofcase study research. Broad-based statistical6
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estimates of the relationshipsbetween upstream funding anddown-
stream performance couldplace this case study evidence onsounder
footing, but these too have theirproblems.
III.Productivity Measurement
Productivity is a natural way to assessthe performance of firms andin-
dustries. High levels of productivityand rapid growth in productivity
are unambiguousindicators of the technological progresswhich public
sector research is intended tosupport. Productivity relates output toin-
put, and publicly fundedresearch affects this relationship in anumber
of ways. Research results,experimental materials, and the humancapi-
tal of highly trained researchers are"free" inputs to the productionof
drugs. At the same time basicresearch improves the efficiencywith
which these inputs are utilized as itidentifies productive areas for in-
vestigation or provides new, moreeffective research tools.
There are good reasons to expect to see animportant impact of pub-
licly funded research in theproductivity statistics for the pharmaceuti-
cal industry. The problem is thatproductivity measurement is besetby
a number ofdifficult problems, which areexacerbated in knowl-
edge-intensive industries with ahigh rate of new productdevelop-
ment. To frame our subsequentdiscussion, we first review these
difficulties.
Measuring Output
Productivity is the ratio of inputs tooutput.1 We begin with the numer-
ator. Measuring output isdifficult in any research-drivenindustry for
two closely related reasons.In the first place, output isconventionally
measured by the sales of the level ofthe firm that produces it. There are
good reasons to believe that thisunderestimates the social value of out-
put. If there are significantexternalities, or "spillovers," thesewill not
be captured in the pricecharged to consumers. Vaccinesprovide a
good example: purchasing theproduct provides private benefits tothe
individual who is vaccinated, but alsosociety benefits from the impact
that vaccination has on loweringthe prevalence of the diseaseor in
the case of smallpox, wiping it outaltogether.
The second problem is thatresearch tends to improve the qualityof
output, and quality improvement may ormay not be reflectedin the
price of output. The computerindustry provides the classicexample ofPublic Funding and PharmaceuticalProductivity 7
this problem: the price ofa standard PC has remainedmore or less
constant over the last 5 years, but thepower and capabilities of the
standard package hasconsistently increasedover time. Statistical
methods for addressing thisproblem have revealed thatthe "true"
quality- adjusted price ofa PC has been falling at a very rapidrate: 20%
per year or more. The same may betrue for pharmaceutical products.
New drugs tend to bemore effective, have fewer side effects,and can be taken in muchmore convenient dosages (onceper day instead of
four times per day). But effortsto apply quality adjustmentsto reflect
these benefits to theconsumer have had limitedsuccess. While the
quality attributes ofa car or a PC are relativelystraightforward to
measure (fuel efficiency, weight,processor speed, storage capacity, etc.)
those of pharmaceuticalproducts are more difficultto define and
measure. (See for example Berndt et al.2000; and Cockburn and Anis
2000.)
For pharmaceuticals,an additional complication is introducedby the
tangled web of economicrelationships between patients,physicians,
pharmacists, and insurers. Insome industries, prices are a reasonably
good measure of consumers'willingness to pay. Here, the linkbetween
expenditures on drugs and the valueto the consumer is harderto draw.
In some cases, the value ofa drug to the patient who receives itmay be
considerably greater than theprice received by the pharmaceutical
company which produces it. (It is alsopossible that some pharma-
ceuticals are worth less to patientsthan the price that is chargedfor them.)
Some researchers have usedmeasures of output such as quality ad-
justed life years (QTJALYs)to correct for these problems,but any
such attempt must inevitablyrest on a series of assumptionsand
judgments that will always beopen to question (Cutler and Richard-
son 1999).
Measuring Inputs
Measuring inputs to theproduction of pharmaceuticalsraises similar
problems. To producepharmaceuticals requires not justperson hours,
capital, energy, materials andso forth, but also "knowledge capital"or
know-how. Measuring knowledgecapital is particularly difficultsince
the impact of knowledge is feltover an extended period of time. Labor
generates output today: but scientificexplorations often only produce
tangible output aftermany years. For example ina study of the impact8
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of scientific research acrossthe entire economy, Adams(1990) found
evidence that on average it takes20 years for basic research toproduce
tangible economic results! In thecontext of the pharmaceuticalindus-
try this problem isparticularly acute. Not only is itthe case that the
lags between the publicationof any particular piece ofpublicly funded
research and its impact on thediscovery of a new drug arelong and
highly variable, but on averageit takes 12-14 years totranslate any
given private sector discoveryinto a drug that can be given topatients.
This problem is particularlyconcrete in the case offederal funding for
molecular biology in general andgenetics in particular. Whilethis
funding has had some immediateimpact on industryproductivity
there is widespread (evenuniversal) agreement that in this casethe
best is yet to come. The interpretationof the human genome, for exam-
ple, is not expected to have adirect effect on human healthfor many
years.
The measurement ofknowledge inputs inpharmaceuticalsand of
the effect of publicly fundedresearch in particularis furthercompli-
cated by the fact that there are amultitude of mechanisms through
which publicly funded researchshapes and supports privatesector
productivity. The most straightforwardis through the developmentof
new scientificknowledge. Figure 1.1 presents amuch simplified dia-
gram of the processof drug discovery and development.
In general, fundamentalresearch (the discovery offundamental sci-
entific knowledge) precedes"drug discovery" (thesearch for com-
pounds that seem to work in testtubes and/or in animals),which is
followed by "drug development"(the process by which onemakes
sure that seeminglyuseful compounds actuallywork safely in hu-
mans). But while it is certainlythe case that publicly fundedresearch
has been responsible forgenerating an enormous amountof funda-
mental science that has supportedmajor breakthroughs in theindustry,
this is by no means the only wayin which public investmentin bio-
medical research has shaped theindustry.
The public sector supports privatesector research through avariety
of other mechanisms. One ofthe most important of theseis the provi-
sion of trained scientists, butthe impact of others shouldnot be over-
looked: public sector sciencealso includes discovery of newresearch
tools, direct investment in asmall amount of drug discoverywork, and
funding of leading edge workin clinical development.
Studies of the relationship betweenuniversities and the private sec-
tor in general havesuggested that one of the most importantoutputs ofPublic Funding and Pharmaceutical Productivity
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Fundamental research:
Does hypertension create health problems?
What is the molecular basis of hypertension?
0
Discovery research:
Can we fmd a compound that appears to tackle
hypertension in a test-tube or in an animal?
0
Figure 1.1
A simple model of drug discovery
the university sector is trainedpersonnel (see for example Agarwal
2000). This is likely to be particularlytrue in the pharmaceutical indus-
try where research is conducted bybattalions of skilled scientists,
many of them with doctorates and postgraduateeducations funded in
large part through NSF and NIHgrants. As industry hires these gradu-
ates it benefits not only from theirgeneral training and skills but also
from the leading edgeaccess it gives them to research being conducted
within the public sector. Anotherimportant publicly funded inputto
the private sector is notnew knowledge, per se (how do virusesme-
tabolize?) but new tools. Cohenand Boyer's discovery ofone of the
most fundamental tools of geneticengineering is one prominentexam-
ple of this phenomenon.
Figure 1.1 suggests that theprocess of drug discovery is an almost
entirely linear one, with scientific knowledgefeeding directly into drug
discovery. In reality, however, theinteraction between the public and
private sectors is muchmore iterative and complex. In Networks of Inno-
vation, for example, Galambos andSewell (1995) show that the devel-
opment of vaccines was characterized bythe continual exchange of
information between researchersworking at Merck and researchers
working in the public sector. Onseveral occasions the development of
novel therapies by the privatesector or advances made in clinical treat-
ment have preceded major advances infundamental knowledge. Brown
and Goldstein's Nobel Prizewinning work on the structure of the LDL
receptor, for example, occurredsimultaneously with the discovery of
the first effective HMG CoAsereductase inhibitors; and therecognition
Clinical Development:
Does this compound reduce hypertension in
humans?10
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that stomach ulcers are bacterialin origin flowed from thepioneering
work of physicians working in theclinic rather than from basic scien-
tific research. Even apparentlystraightforward cases such as the dis-
covery of AZT appear, oncloser examination, to have afine grained
structure that reflects abidirectional flow of knowledge ratherthan the
simple transmission of researchresults or new ideas from thepublic to
private sectors (Cockburn andHenderson 1998).
This bidirectional structure notonly complicates the problemof im-
posing a time structure onthe estimation of the effect of publicresearch
(see below). It also hints at anotherimportant role of public research:
the maintenance of a communityof researchers, or a public rankhierar-
chy in which private sectorresearchers can be evaluated andpromoted
on the basis of theirstanding in the public communityof science. As
the techniques of drug discoveryevolved and it became increasingly
important to be able to takeadvantage of the findings of publicscience,
the most productivepharmaceutical firms began to rewardtheir re-
searchers on the basis of theirstanding in the eyes of their peers
(Henderson and Cockburn 1994;Cockburn, Henderson, and Stern
2000). To some degree the adoptionof this incentive mechanism un-
doubtedly reflects the fact that it encourages afirm's scientist to pub-
lish and to engage with thecommunity of public scientists, andthis in
turn facilitates the firm'sability to take advantage ofpublicly gener-
ated knowledge. But its adoptionalso probably solves a difficultprob-
lem for managers: evaluating theeffort and performance of scientific
professionals whose work is becomingincreasingly complex and in-
creasingly difficult to monitor. Tothe degree that these practices
increase the flexibility andcreativity of the private sector, themainte-
nance of a publiccommunity of science acts as aninput (of a particu-
larly subtle kind) to the private sector.
Arguably, the presence of thecommunity of open science also pro-
vides an implicit subsidy to theindustry in that it provides important
nonmonetary rewards. Scott Stern(Stern 1999) has shown that re-
searchers are willing to trade salaryfor the opportunity to work onsci-
entifically interesting projects. Sincesalaries are a large fraction of total
research costs, to the extent thatthis phenomenon drives downthe
wages demanded byscientists, the industry benefits.
The public sector also invests inthe actual discovery of new drugs
through its support of screening programssuch as that conducted by
the National Institute for Cancer.While this program hasgenerated
one important newdrugTaxolitS overall impact appears tobe min-Public Funding and Pharmaceutical Productivity
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imal. Last, but by nomeans least, the public sector supports private
sector productivity through thesupport of clinical development and
clinical research. There issome evidence that this type of researchpro-
vides a critically important stimulusto the discovery of new drugs
(Wurtman and Bettiker 1994, 1996).
The measurement of knowledgecapital is further complicated by the
problem of "spillovers,"or the fact that knowledge generated inone
place or firm is often useful elsewhere.At the level of the entireecon-
omy this effect is unproblematic, but whenone is trying to measure the
impact of spillovers from publicly fundedresearch on a particular firm,
for example, it raises seriousproblems. Where shouldone look for
spillovers? One importantsource may be a firm's competitors. In the
case of pharmaceuticals, for example,we showed that private sector re-
search productivity was directly andsignificantly affected by competi-
tive research activity (Hendersonand Cockburn 1996). Then thereis
the question of whether totreat all federally funded entities equally,or
to trace spillovers only to those thatare geographically or technically
"close." And while the U.S.government accounts for a substantial frac-
tion of worldwide publicsector research, science is a globalenterprise.
Contributions from significant publicly fundedresearch activity in Eu-
rope and elsewhere ought not to be ignored.
Despite these problems,a number of researchers have attempted
to use productivity measures toestimate the rate of return to publicly
funded research. Studies at theaggregate level, or at the level of the
entire economy, generate numbersin the 20-40% range,as described
above. As an illustration of theseresults, table 1.2 reproduced from
Grifiches 1995, summarizes theresults from a number of studiesof
industry productivity. The resultsvary widely, but seem to suggest
that the rate of return to publicresearch is likely to be quite high.2
IV.The Role of Publicly Funded Researchin the Pharmaceutical
Industry
Attempts to measure the role of publiclyfunded research in the context
of the pharmaceutical industrymust not only grapple with these is-
sues, but must also take account ofan environment in which the rela-
tionship between the publicand privatesector has changed
dramatically over the last 50years.
Public funding for health relatedresearch is largely a product of the
Second World War. Before thewar the pharmaceutical industrywasAgriculture
Rate of return to public R&D
Griiches (1958) Hybrid corn 35-40
Hybrid sorghum 20
Peterson (1967) Poultry 21-25
Schmitz-Secker (1970) Tomato harvester 37-46
Griiches (1964) Aggregate 35-40
Evenson (1968) Aggregate 41-50
Knutson-Tweeten (1979) Aggregate 28-47
Huffman-EvensOn (1993) Crops 45-62
Livestock 11-83
Aggregate 43-67
Rate of return to all R&D
Industry
Case studies
Mansfield et al. (1977) 25-56
1-0 Weighted









Differs by industry 9-160
Bernstein-Nadiri (1991) 14-28
Table 3.4 from Griliches, 1995.
not tightly linked to formalscience. Until the 1930s,when sulfonamide
was discovered,drug companies undertook littleformal research. Most
new drugs werebased on existing organicchemicals or were derived
from natural sources (e.g.,herbs) and little formal testing wasdone to
ensure either safety orefficacy. Harold Clymer, whojoined SmithKline
(a major American pharmaceuticalcompany) in 1939, noted:
[YIlou can judge the magnitudeof [SmithKline'sI R&D at that timeby the fact I
was told I would have toconsider the position temporary sincethey had al-
ready hired two people within theprevious year for their laboratoryand were
not sure that the businesswould warrant the continued expenditure.(Clymer,
1975)
World War II and wartime needsfor antibiotics marked the drug in-
dustry's transition to an R&Dintensive business. Penicillin and itsanti-




Selected estimates of returns to R&D andR&D spilloversPublic Funding and Pharmaceutical Productivity
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However, throughout the I 930s,it was produced only in laboratory
scale quantities and was used almostexclusively for experimentalpur-
poses. With the outbreak of World War II, theU.S. government orga-
nized a massive research andproduction effort that focusedon
commercial production techniques andchemical structure analysis.
More than 20 companies, severaluniversities, and the Department of
Agriculture took part.
The commercialization ofpenicillin marked a watershed in thein-
dustry's development. Due partiallyto the technical experience andor-
ganizational capabilities accumulatedthrough the intense wartime
effort to develop penicillin,as well as to the recognition that drug de-
velopment could be highly profitable,pharmaceutical companiesem-
barked on a period of massiveinvestment in R&D and built large-scale
internal R&D capabilities. At thesame time there was a very significant
shift in the institutional structuresurrounding the industry. Whereas
before the war publicsupport for health related research had been
quite modest, after the war it boomedto unprecedented levels. Thepe-
riod from 1950 to 1990was a golden age for the pharmaceutical indus-
try, as for industry in general, andparticularly the major U.S.
playersfirmssuchasMerck,EliLilly,Bristol-Myers,and
Pfizergrew rapidly and profitably. R&Dspending exploded and with
this came a steady flow ofnew drugs. (Figure 1.2 shows publicly
funded spending on health relatedresearch and total U.S. R&D spend-
ing by U.S. pharmaceutical firms.3)
A number of factors supported theindustry's high level of innova-
tion. One was the sheer magnitudeof both the research opportunities
and the unmet needs. In the earlypostwar years, there were many dis-
eases for which no drugs existed. Inevery major therapeutic cate-
goryfrom painkillers andanti-inflammatories to cardiovascular and
central nervous systemproductspharmaceutical companies facedan
almost completely open field (beforethe discovery of penicillin,very
few drugs effectively cured diseases).
Faced with such a target richenvironment but very little detailed
knowledge of the biologicalunderpinnings of specific diseases, phar-
maceutical companies iiwentedan approach to research now refer-
red to as "random screening."Under this approach, naturaland
chemically derived compoundsare randomly screened in test tube
experiments and laboratory animals forpotential therapeutic activ-
ity. Pharmaceutical companiesmaintained enormous libraries of chem-
ical compounds, and addedto their collections by searching for










































































































































































































5Public Funding and PharmaceuticalProductivity 15
Thousands, if not tens of thousands,of compounds might be subjected
to multiple screens before researchershoned in on a promising sub-
stance. Serendipity playeda key role since in general the "mechanism
of action" of most drugsthespecific biochemical and molecularpath-
ways that were responsible for their therapeuticeffectwere not well
understood. Researcherswere generally forced to rely on theuse of an-
imal models as screens. For exampleresearchers injected compounds
into hypertensive ratsor dogs to explore the degree to which theyre-
duced blood pressure. Under thisregime it was notuncommon for
companies to discover a drug to treatone disease while searching for a
treatment for another. Althoughrandom screeningmay seem
inefficient, it worked extremely wellfor many years, and continuesto
be widely employed. Several hundredchemical entities were brought
to the market in the 1950s and 1960s andseveral important classes of
drug were discovered in thisway, including a number of important di-
uretics, all of the early vasodilators,and a number of centrally acting
agents including reserpine and guanethidine.
In general, this early form of randomscreening made only delayed
and indirect use of the results ofpublicly funded research. Beginningin
the early 1970s, the industry beganto benefit more directly from theex-
plosion in public funding for healthrelated research that followed the
war. Publicly funded research had always beenimportant to the indus-
try's health, but initially itwas probably most important as asource of
knowledge about the etiology of disease.For example it was the pub-
licly funded Framingham heartstudy that showed that elevated blood
pressure (hypertension) was associated witha greater risk of heart dis-
ease and death, and thus encouraged theindustry to search for drugs
that might tackle it.
From the middle 1970son, however, substantial advances in physiol-
ogy, pharmacology, enzymology, and cellbiologythe vast majority
stemming from publicly fundedresearchled to enormousprogress in
the ability to understand themechanism of action ofsome existing
drugs and the biochemical andmolecular roots of many diseases. This
new knowledge made it possible to designsignificantly more sophisti-
cated screens. By 1972, forexample, the structure of the renin
angiotensive cascade, one of the systemswithin the body responsible
for the regulation of bloodpressure, had been clarified by the work of
Laragh and his collaborators (Laraghet al. 1972) and by 1975 several
companies had drawn on this research indesigning screens for hyper-
tensive drugs (Henderson and Cockburn1994). These firms could16
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replace ranks of hypertensive ratswith precisely defined chemical re-
actions. In place of the request"find me something that willlower
blood pressure in rats" pharmacologistscould make the request "find
me somethingthat inhibits the action of theangiotensin 2 converting
enzyme."
The more sensitive screens in turnmade it possible to screen awider
range of compounds.Prior to the late 1970s, forexample, it was
difficult to screen the natural productsof fermentation (a potent source
of new antibiotics) in wholeanimal models. The compounds were
available in such small quantitis, ortriggered such complex mixtures
of reactions in living animals,that it was difficult to evaluatetheir ef-
fectiveness. The use of enzyme systems asscreens made it mucheasier
to screen these kinds ofcompounds. It also triggered a virtualcycle in
that the availability of drugswhose mechanisms of action werewell
known made possible significantadvances in the medicalunderstand-
ing of the natural historyof a number of key diseases,which in turn
opened up new targets and opportunitiesfor drug therapy.
Both "random" and "guided" or"science driven" drug discovery
continue to be important tools inthe search for new drugs,4 butthe
most important developmentin the pharmaceuticalindustry is the
advent of the science andtechniques of biotechnologyandin this
field the role of publiclyfunded research is even morepronounced.
Historically, most drugs have beenderived from natural sources or
synthesized through organic chemistryAlthough traditional produc-
tion methods (includingchemical synthesis and fermentation)enabled
the development of a wide rangeof new chemical entities and many
antibiotics, they were not suitablefor the production of most proteins.
Proteins, or molecules composedof long interlocking chains of amino
acids, are simply too largeand complex to synthesize feasiblythrough
traditional synthetic chemical methods.Those proteins that were used
as therapeuticagentsnotably insulinwere extractedfrom natural
sources or producedthrough traditional fermentationmethods. How-
ever, since these processes(which were used to produce manyantibiot-
ics) could only utilize naturallyoccurring strains of bacteria, yeast, or
fungi, they were not capable ofproducing the vast majority of proteins.
Cohen and Boyer's (publiclyfunded) key contribution was the inven-
tion of a method for manipulatingthe genetics of a cell so that itcould
be induced to produce aspecific protein. This invention madeit possi-
ble for the first time toproduce a wide range of proteinssynthetically
and thus opened up an entirely newdomain of search for newPublic Funding and Pharmaceutical Productivity 17
drugsthe vast store of more than 500,000proteins that the body uses
to carry out a wide range of biological functions.
In principle these new techniques ofgenetic engineering thus
opened up an enormous new arena for research.However the precise
function of the majority of these proteins isstill not well understood,
and the first firms to exploit the new technologychose to focus on pro-
teins such as insulin, human growth hormone, tPA,and Factor VIII
for which scientists hada relatively clear understanding of the bio-
logical processes in which theywere involved and of their probable
therapeutic effect. This knowledge greatly simplifiedboth the process
of research for the first biotechnology-based drugsand the process of
gaining regulatory approval. It also made it mucheasier to market the
drugs since their effects were well known anda preliminary patient
population was already in place.
As firms and researchers gain experience with thenew science, how-
ever, it has had increasingly dramatic impacts on theways in which
new drugs are discovered. For example the techniques of geneticengi-
neering allow researchers to clone targetreceptors, so that firms can
screen against a pure target rather than against, for example,a solution
of pulverized rat brains that probablycontain the receptor. They can
also allow for the breeding of ratsor mice that have been genetically al-
tered to make them particularly sensitiveto interference with a particu-
lar enzymatic pathway. Both of these techniques allowfor the design of
greatly improved "screens" against which compoundscan be tested for
therapeutic activity.
A second strategy has been to focuson a specific disease or condition
and to attempt to finda protein that might have therapeutic effects.
Here detailed knowledge of the biology ofspecific diseases is an essen-
tial foundation for an effective search. Forexample researchers work-
ing in cancer, AIDS, and autoimmune diseases havefocused on trying
to discover the proteins responsible for modulatingthe human im-
mune system. A third strategy is to focus on genomicstheuse of
knowledge of the human genetic code touncover new treatments for
disease. This strategy is only at the most preliminarystage, but it prom-
ises to revolutionize the treatment ofmany diseases.
Taken together, these events have moved publicresearch from an im-
portant but distant foundation for drug discovery toa critically impor-
tant source of immediately useful knowledge andtechniques that is
actively engaged by the private sector. Table 1.3 andfigures 1.3 and 1.4
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histories of the discoveryand development of 21 drugsidentified by two leading industryexperts as "having had themost impact upon
therapeutic practice" between1965 and 1992. The tableconfirms the
important role that the publicsector plays in providing fundamental
insights in basic knowledgeas a basis for drug discovery. Onlyfive of
these drugs, or 24%,were developed with essentiallyno input from the
public sector. (Thiscontrasts with Maxwell and Eckhardt'sfinding (Maxwell and Eckhardt1990) that 38% of their sampleof older drugs
were developed with no public sectorinput.) In the second place,these data are consistent with thehypothesis that public sectorresearch has become more importantto the private sectorover time. The table
groups the drugs into three classesaccording to the researchstrategy by which theywere discovered: those discovered byrandom screen-
ing, those discovered bymechanism-based screening, andthose dis- covered through fundamentalscientific advances. Broadlyspeaking, the degree of relianceon the public sector for the initialinsight in-
creases across the three groups, andas the industry has moved toa greater reliance on the secondand third approaches,so the role of the
public sector has increased. Inthe first group oftherapiesthose dis- covered through "randomscreening"publjc sector researchersmade the key enabling discoveryin only two of the fivedrugs. In the two
more recent groups public sectorresearchers made the key discoveryin all but two of thecases. The very long lagsapparent in the table be-
tween fundamental advancesin science and theirincorporation in
marketed products may beshortening as the public andprivate sectors
draw closer together, but itis difficult to draw strongconclusions from this small sample.
One way to capture interactionbetween the public sectorand indus- try is via the paper trail ofpublications by pharmaceuticalcompany re- searchers in the open literature.Publication is a key indicatorof participation in the widerscientific community, and inour studies of
the management ofresearch in a sample ofmajor pharmaceutical
firms, we found evidencefrom analysis of these"bibliometric" data
that this participation has becomemore and more significantover time.
Figure 1.3 shows four keymeasures of this dimension of the relation-
ship between the public andprivate sector in the industry,and tracks
their evolution over time. "Propub" is a measure of the degreeto which
the firm relies on its scientists'standing in relationshipto public sci- ence as a key criteria inpromotion decisions (Hendersonand Cockburn i994)6 "Stars" isthe average number ofscientists at eachCockburn and Henderson
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firm who publish morethan 25 papers within anygiven three year pe-
riod. "Pubfrac" is the percentageof all those scientists whose namesap-
pear on a patentin any given yearwhose name also appears on
scientific publication.7"Univ-coauth" is the averagepercentage of the
firm's papers that arecoauthored with universityauthors.8 All of these
measures increasesignificantly over the period,illustrating graphically
the private sector'sincreasing engagement withthe world of publicly
available (and largely publiclyfunded) research. Figure 1.4illustrates
one result ofthis dynamic: the numberof papers per patent and papers
per NDA (NewDrug Application) hasalso steadily increased overthe
period.
V What, then, can wesay?
The estimation of theeffect of publicly fundedresearch on the produc-
tivity of the pharmaceuticalindustry thus presentsformidable chal-
lenges. It is verydifficult to accurately measureeither inputs or
outputs: there are verylong and highly variablelags in the relationship
between inputs and outputs,and furthermore the natureof this rela-
tionship has likely changeddramatically over time.
Research in this area has thusproceeded along three lines.The first is
the broad brush comparisonof the United States withthe rest of the
world. The second, perhaps notsurprisingly is the detailed casestudy.
The third is econometric orstatistical. All three suffer fromlimitations,
but taken together theysuggest that publiclyfunded research has a
very significantimpact on the generationof new drugs.
Regional Comparisons
One of the intriguingaspects of the revolutionin molecular biologyis
that despite the fact that itis global in nature,and despite the fact that
scientific advances arenormally thought of as creating a"free good,"
or as beinginstantaneously availableworldwide, it has resulted in
quite different changes inindustry structure indifferent parts of the
world. In the U.S., it hasspawned both the emergenceof radically new
actorsthe new specializedbiotecimologY firmsand thegradual cre-
ation of biotechnology programswithin established firms. InEurope,
responses havediffered dramatically fromcountry to country.Despite
a strongresearch tradition inmolecular biology, in generalEurope has
not witnessed thecreation of a specializedbiotechnology sector. Sev-
eral of the leading Swissand British "Big Pharma"incumbent firmsPublic Funding and PharmaceuticalProductivity 23
have attempted to buildstrong biotechnologycapabilities through a
combination of internal developmentand an aggressiveprogram of ex-
ternal acquisition, but theFrench, German, and Italianfirms have been
much slower to adopt thenew techniques. In Japan, wherehistorically the pharmaceutical industryhas been somewhat lessinnovative than its Western rivals, mostsubstantial investments inbiotechnology have been made by firms withhistorical strengths infermentation based in- dustries, and the largepharmaceutical companies havebeen particu- larly slow to embrace thenew technology.
The question of why thephenomenon of the small,independently funded biotechnologystartup was initially an Americanone is an old
and much discussed question.One of the reasons that itcannot be an-
swered definitively is that theanswer is to a large degreeover deter- mined. In the United Statesa combination of factors madeit possible for small, newly foundedfirms to take advantage ofthe opportunities created by biotechnology.
On the one hand, themajority of the Americanbiotechnology startups were tightly linkedto university departments,and the very strong state of Americanacademic molecular biologyclearly played an
important role in facifitatingthe wave of startups thatcharacterized the eighties (Zucker, Darby,and Brewer 1997). Thestrength of the local
science base may also beresponsible, within Europe, for therelative
British advantage and therelative German and Frenchdelay. Similarly
the weakness of Japaneseindustry may partially reflectweakness of Japanese science. Thereseems to be little questionas to the superiority
of the American and Britishscientific systems in the fieldof molecular biology, and it is temptingto suggest that the strengthof the local sci-
ence base provides an easy explanationfor regional differencesin the speed with which molecularbiology was exploitedas a tool for the
production of large molecularweight drugs.
On the other hand,a number of other important factorssupported the new firms' growth. Thesefactors includeda favorable financial cli-
mate, strong intellectualproperty protection, a scientific andmedical establishment that couldsupplement the necessarily limitedcompe- tencies of small newly foundedfirms, a regulatory climatethat did not restrict geneticexperimentation, and, perhapsmost importantly,
a combination of a very strong localscientific base withacademic and cultural norms thatpermitted the rapid translationof academicre- suits into competitiveenterprises. Nelson (1993) has labeledthis a "na- tional system of innovation,"and it appears to havebeen particularly
conducive to innovation inbiotechnology. In Europe (althoughto aCockburn and Henderson
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lesser extent in the U.K.)and in Japan many of thesefactors were not
in place. For example,for many years the patentabilityof various as-
pects of biotechnology wasuncertain in Europe, anduntil recently
there was a relativelysmall local venture capitalindustry In general,
it was left to largerfirms to exploit the newtechnology in these
countries.
Case Study ResearchThere have also been asignificant number of
careful case studies of this issue,most focused on thedevelopment of
detailed histories of the discoveryof new drugs. See forexample Borel,
Kis, and Beveridge 1995,Comroe and Dripps 1976,Penan 1996, Raiten
and Berman 1993, Richardsonet al. 1990, and Rittmaster1994. By trac-
ing the involvement ofparticular individuals or laboratoriesin the dis-
covery of a particulardrug it is possible, at least inprinciple, to identify
and evaluate the relativeimportance of privatelyfunded versus pub-
licly funded research. Of course,the exercise can be verydifficult in
practice, and is unlikely toproduce unambiguous conclusions.
Consider the case of AZT, thefirst drug to approved bythe FDA for
use in treatmentof HIV infection. AZT wasfirst synthesized in the
early 1960s by a public sectorresearcher looking for activityagainst
cancer. It thenlanguished for many years inthe library of compounds
maintained by antiviralresearchers at BurroughsWelicome. Its value
in prolonging the lifeof some AIDS patientsonly became apparent
when BW sent it, alongwith a dozen other candidatecompounds, for
testing against a screendeveloped at NIH. BW thentook the lead in
conducting clinical trialsand obtaining FDAapproval. "Who discov-
ered what and when" was anintegral part of the intense controversy
surrounding this case, with theU.S. Supreme Courteventually ruling
against claims that NIHscientists should have beenlisted as inventors
on BW's patents onthe use of AZT in treatmentof AIDS.
Legal claims aside, debatesabout priority in discovery are aninte-
gral part of science, anddifferent observers mayplace more or less
weight on different contributions.In many instances, it issimply im-
possible to definitively assigncredit for the invention of adrug to a
specific individual or institution.Furthermore, many of these casehis-
tories overlook the subtlerinfluences of the public sectorin providing
"infrastructure," graduate training,and so forth. But betweenthem
these studiesand otherslike themmake a compellingquantitative
case for the importanceof publicly funded research.All of them sug-
gest that publiclyfunded research made criticalcontributions to the
discovery of an importanttherapeutic advance.Public Funding and PharmaceuticalProductivity 25
Econometric or Statistical StudiesEconometric studies of the impact of
publicly funded researchon private sector productivity supplement
the particularity ofcase studies with more general results, butare sub-
ject to all of the problems thatwe outlined above. Figures 1.5 and 1.6
hint at some of the issues thatmust be dealt with in interpretingthe
raw quantitative data. Both figures showthat several keymeasures
of the output of theindustrypapers, patents, and NDAs,or New
Drug Approvalshave beenincreasing over time.9 But all threemea-
sures involve considerable error,1° all threemeasures trend up quite
smoothly over time, and all threeare only loosely related to social im-
pact. Presumably we care aboutpatient health, not papers,patents, or
NDAs per Se, and while there isalmost certainly some link betweenthe
two, at any general level it isimpossible to be precise aboutwhat it
might be. Similarly thereare the long lags to consider: the NDAsap-
proved tomorrow will reston research that was performed anywhere
from 5 to 15 yearsago, and since both private and publicresearch
trends up over time it isvery difficult to separately identify their
effects.
Despite these difficulties,a number of researchers have attemptedto
measure the effects of public sectorresearch directly. Zucker, Darby,
and Brewer (1997) show thatbiotechnology startups tend toco-locate
with public sector researchers,an intriguing and suggestive result.
Zucker, Darby, and Armstrong(1998) show further thatcollaborations
between these new firms anduniversity stars is correlated withsome
measures of success. For anaverage firm, five articles coauthored by
academic stars and the firm's scientistsimply about five more products
in development, 3.5more products on the market, and 860more em-
ployees. These resultsare consistent with the hypothesis thatuniver-
sity research has a powerful effecton the private sector, though they
should be interpretedcarefullythe authors were not ableto fully con-
trol for the level of R&Dspending by the firmsor the quality of their
other scientists.
Two studies have exploredanother indirect measure of publicsector
impact: the relationship betweena firm's ability to take advantage of
knowledge generated in the publicsector and its own productivity.
Gambardella (1995) showed that in the1970s and 1980s those pharma-
ceutical firms that publishedmore scientific papers were relatively
more productive than their rivals. Ina similar vein, in Cockburn and
Henderson (1998)we explored the relationship betweena firm's
research productivity and its"connectedness" to the publicsector,





















































































































































































































































































































































































































































boundaries. "Connectedness"in this sense is closelyrelated to a num-
ber of other factors thatalso increase the productivityof privately
funded pharmaceuticalresearch, including the numberof star scien-
tists employed by the firmand the degree to which thefirm uses stand-
ing in the public rankhierarchy as a criterion forpromotion. Linking
these data with measuresof research productivity wefound that
"connectedness" and research performanceare correlated acrossfirms
and over time. While anyestimate of this type mustbe treated with
great caution, our resultsalso suggested thatdifferences in the effec-
tiveness with which a firm wasaccessing the upstream pooiof knowl-
edge corresponded to differencesin the research productivityof firms
in our sample of as much as30%.
One interpretation of thisresult is that it represents alower bound
estimate of the impact ofpublic sector research, sinceby definition it
excludes the impact of anypublicly generated knowledgethat can be
costlessly accessed acrossthe industry. Howeverthe factthat
"connectedness" is likely to becorrelated with other hard-to-observe
organizational practices that improveresearch productivitY as well as
other important sourcesof unobserved heterogeneity acrossfirms
(such as the quality of humancapital) made us hesitate to assignthe re-
sult too much weight.Rather we suggested that ourresults were con-
sistent with the hypothesisthat the ability to takeadvantage of
knowledge generated in thepublic sector requires investmentin a
complex set of activities thattaken together change the natureof pri-
vate sector research. Theythus raise the possibility thatthe wiys in
which public research isconducted may be as important asthe level of
public funding. To the extentthat efforts to realize adirect return on
public investments in researchlead to a weakening of theculture and
incentives of "open science," ourresults are consistent withthe
hypothesis that the productivityof the whole system ofbiomedical
research may suffer.
In a study at a moreaggregate level, Ward and Dranove(1995)
showed that a 1% increase inresearch funding by theNational Insti-
tutes of Health leads to anestimated 0.6-0.7% increase inspending by
members of the PharmaceuticalManufacturers of America(PMA), af-
ter a lag of 6 to 10 years.This result is also consistentwith the hypothe-
sis that the private return topublicly funded research isquite high,
since if increases in publicsector research fuel privatesector increases,
then presumably the presenceof public sector research israising the
marginal productivity of privatesector work.Public Funding and PharmaceuticalProductivity 29
The most recentpaper in this stream of research is byAndrew Toole
(1999). Toole uses dataat the level of the therapeuticclass to obtain esti-
mates of the rate of returnto publicly funded research.His (unpub-
lished) estimates imply thata 1% increase in the stock of publicbasic
research ultimately leads toa 2.0% to a 2.4% increase in the numberof commercially available newcompounds, and that industryfirms ap- propriate a return on publicscience investment in therange of 11 % to 32%. He notes that thisresult suggests that thereturns to public science
are actually rather larger since theseestimates are basedon conserva-
tive estimates of firm profitsfrom an averagecompound and since they
ignore any consumer surplusthat may be created by theintroduction of a new therapy.
Conclusions We have suggestedthat there are a number offactors that make it difficult to estimateprecisely the impact of publiclyfunded re-
search. Such estimation isalways difficult, but in thecase of the phar-
maceutical industry it isa notably difficult task since thepublic sector provides inputs to industryresearch in so many differentand subtle
ways, and spillovers are likelyto be so large that the socialreturns to innovation are substantiallydifferent from themeasurable private returns.
Nevertheless, a considerable bodyof both qualitative andquantita- five evidence indicates thatthe public sector has hada profoundly pos-
itive impact on the industry,and that this appearsto have increased
significantly over time. Qualitativeevidence suggests that publicsector research has made possiblefundamental advances in theways in which new drugsare discovered and has openedup doors that may
revolutionize the treatment of disease.The quantitative evidencesug- gests that the rate of return topublic sector researchas measured by its ef-
fect on the private sector,may be as high as 30%.
There are a number ofreasons for believing that this figureis in fact a
quite conservative estimateof the overall socialreturn to publicly
funded research in thissector of the economy. First, it ishighly unlikely
that private sector firmscapture all of the benefits topublic sector re- search in their own output.When drugs come offpatent, to take one
example, their price tendsto fall considerably, but thebenefit to con-
sumers in terms of QUALYsor other measures of health statusremains constant. Thus "true" output islikely to be seriouslyundercounted,
and economic estimates of thebang for the buck frompublicly funded
research will therefore, if anything,be lower bounds to thereal value.Cockburn and Henderson
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Second, the lag between whenbasic scientific advances aremade and
when their impact becomesvisible in marketed productsis particularly
long in this industry.Despite intense commercialcompetition and the
dedicated effort of manythousands of individuals, it cantake 10 years
or more forpromising discoveries tobe turned into approveddrugs.
Today's improvements intreatment of many diseasesreflect public re-
search expenditures made inthe1960sand1970s.The bulk of the im-
pact of the investmentsmade in the1980sand1990shas probably not
yet been felt. Arguably, wehave yet to benefit fromthe most important
contribution of modernpublicly funded science:the breakthrough in
our understandingof genetics and molecularbiology that is summa-
rized under the name "thebiotechnology revolution."There are hun-
dreds of new compoundsin development thatdraw upon this
knowledge, and surelythousands more yet to bediscovered. Econo-
metric studies conducted10 or 20 years from now arelikely to find
even higher ratesof return to publiclyfunded research.
Over the past 50 years,the pharmaceutical industryand the publicly
funded biomedical researchestablishment have grownhand in hand in
their size and economicsignificance. Ever larger investmentsin re-
search on both sides haveresulted in new drugs andvaccines that are
responsible for very significantimprovements in healthand well-
being. This remarkableinnovative performance isunlikely to have
been realized withoutsubstantial public support ofbasic research,
along with the developmentof close linkages betweenprivate sector
and public sector institutions.
The relationships betweenthe NIH, government labs,universities,
and the private sectorcontinue to evolve, and areasof conflict have in-
evitably arisen. In genomeresearch, for example, privatefirms have
been seeking proprietaryrights over some of theresults of decades
of publicly fundedwork on DNA sequencing.Equally, universities
have become increasinglyaggressive and effective inrealizing licens-
ing revenue from theirdiscoveries. These changes arealtering the deli-
cate balance betweennonprofit and for-profitinstitutions which
appears to have been soeffective in the past atgenerating scientific ad-
vances and bringingthem to market, and aresurely a cause for some
concern.
Nonetheless, absent anyevidence of exhaustionof scientific oppor-
tunities, there is a compelling casefor continued substantialpublic
support of the biomedicalsciences. As today's taxpayersreach retire-Public Funding and PharmaceuticalProductivity 31
ment age they will enjoy agenerous return from these investments, but
if the experience of thepast five decades is any guide itwifi be their
children and their children'schildren who will benefit themost.
Notes
This paper was prepared for the NBERConference on Science and Public PolicyWash- ington, D.C., April 2000. This studywas funded by POPI, the Program for the Studyof the Pharmaceutical Industry at MITand by the MIT Center for Innovationin Product De- velopment under NSF CooperativeAgreement Number EEC-9529140. Thissupport is gratefully acknowledged. Jeff Furmanprovided outstanding research assistance.
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The preferred embodiment of thisidea expresses productivity interms of a produc- tion function which models outputas a function of inputs. These functionscan be quite elaborate, allowing for returnsto scale, substitution between inputs,etc. Estimation of these functions raises a further set ofproblems, see, e.g., Griliches, 1979, 1994,1995.
The vagueness of this statement reflectsthe very considerable methodologicalprob- lems inherent in these types of studies.To give a taste of these, consider thestatistical problems iitherent in trying toeconometrically estimate production functionsin which measures of publicly funded knowledge capitalappear as an input. Even if accurate
measures of inputs and outputs can be found,getting accurate estimates of theparame- ter values which tell us about the rateof return to public research isvery difficult. For ex- ample, in general, measures ofoutputs and inputs tend to be correlatedwith each other and to move together over time. Thismakes it hard to determine the directionof causal- ity: does research cause salesor do sales cause research? Even if there is sufficientinde- pendent variation in these variables, itis far from clear what the appropriatefunctional form of the production function mightbe.
Most major pharmaceuticalsare multinational, performing R&D inmore than one country These figures do not includean additional 10-20% of overseas R&D spending
by U.S-headquartered firms,or expenditures in the U.S. by foreign-based firms.
Indeed the development of "combinatorialchemistry" coupled with the techniquesof "high throughput screening" havegiven a new lease of life to randomdrug discovery.
For purposes of general comparisonwe list a date of key enabling discovery foreach drug. The choice of any particularevent as the key enabling discovery is boundto be contentious, since in pharmaceuticals,as in many fields, discovery usually restson a complex chain of interrelatedevents. In the case of drugs discovered throughscreening we give the date of first indication of activity ina screen. In the case of mechanism based
drugs, we give the date of the first cleardescription of the mechanism. Dates forthe third class are only broadly indicative, andall should be used carefully
"Propub" was constructed using detailedqualitative data at 10 major pharmaceutical
firms. For details, see Henderson andCockburn 1994.
"Stars" and "Pubfrac" wereconstructed using publicly available data from19 large pharmaceutical firms. For details,see Cockburn, Henderson, and Stern 2000.
This variable is constructed for thesame sample of 10 major firms for which "Propub"
was constructed, using publicly available data. SeeCockburn and Henderson 1998.32
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Industry sales have also beenincreasing, at roughly the same rate asprivate R&D
spending. Recall, however, that thelag between R&D spendingand the generation of
sales is a very long one!
We show here only NDAs thatwarrant Class I or Class 2ranking by the FDA
entirely new therapies of considerablemerit and therapies that areessentially equivalent
to existing therapies.
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